


Rapid-Start Program for Activ-Blister™ Solutions

Accelerating Time-to-Market and De-Risking Drug Product Development with Aptar CSP Technologies and PCI Pharma Services

The Rapid-Start Program provides pharmaceutical developers with a quick and cost-effective solution for determining the feasibility of using Activ-Blister™ solutions to solve their oral solid dose drug stability challenges.

BENEFITS OF THE PROGRAM

- **Expedite Process**
Delivered in as little as 4 weeks
- **De-Risk Development**
Co-investment by Aptar CSP and PCI enables a low cost solution to determine feasibility of your drug product using Activ-Blister™ solutions
- **Streamline Specification Selection**
Fully adapted to customer drug product sizes 0, 1, 2, 3



Simple
Process



Cost Efficient
Solution



Fast Sample
Production

DELIVERABLES AND FEATURES

- 100-200 blister cards (1x5 or 1x7) housing 500-1,000 doses
- Activ-Blister™ technology adhered via proprietary heat-staking process

Sample blister cards are suitable for:

- User/comparison studies
- Formulation selection
- QBD and iteration
- Proof of concept testing (i.e., moisture protection for product)
- R&D go/No-go evaluation
- R&D stability testing

PROGRAM SPECIFICATIONS

- **Capsule Sizes:**
0, 1, 2, 3 or round tablet
- **Blister Type:**
Thermoform or cold form blister
- **Blister Layout:**
1x5 or 1x7
- **Standard Tooling**
- **Formulations:**
Moisture adsorbing, O₂ scavenging or combination
- **EAS Clinical Line**
- **Activ-Film™ Thickness:**
0.3mm, 0.6mm, 0.8mm, 1.0mm, 1.2mm, 1.6mm or 2.0mm

HOW TO GET STARTED



If necessary, sign 3-Way CDA with Aptar CSP Technologies and PCI Pharma Services



Complete intake form questionnaire



Samples delivered in as little as 4 weeks after receiving API and components

csptechnologies.com | pci.com

Activ-Blister is trademark owned by CSP Technologies, Inc., a wholly owned subsidiary of AptarGroup, Inc.

Aptar 
CSP Technologies

pci
PHARMA SERVICES